Menu
← Oncology Approval Tracker
FDA DECISION ·
Braftovi + Erbitux
encorafenib + cetuximab · Array BioPharma
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic colorectal cancer with a BRAF V600E mutation identified by an FDA-approved test after prior therapy.
LAMPGEN ANALYSIS
Why it matters
Established a BRAF-directed combination for a previously treated colorectal cancer population.
What research teams should watch
Record the precise BRAF variant and coordinate oral drug supply with infusion visits.
PRIMARY RECORDS